Phase 2/3, Multistage, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel Group Withdrawal Study to Evaluate the Efficacy and Safety of Nipocalimab Administered to Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 28 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nipocalimab (Primary)
Indications Chronic inflammatory demyelinating polyradiculoneuropathy
Focus Registrational; Therapeutic Use
Acronyms ARISE study
Sponsors Janssen Research & Development; Janssen-Cilag

Most Recent Events

20 Jul 2023 Planned primary completion date changed from 11 May 2026 to 14 May 2027.
27 Apr 2023 Trial design presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
08 Sep 2022 Planned initiation date changed from 25 Jun 2022 to 15 Sep 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight